Full history for every metric is available with a Kvantra account

Stock profile
Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated (LGND)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
128.1
History
P/E NTM
N/A
Market cap
5.74B
Currency USD
KvantraRankAbout65
IValue60
IIQuality61
IIIMomentum78
Current price
286.85 USD-0.03%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m164242196131167268254292
Operating profit$m47.230.2
Net profit$m-357-3352-412451-
EPS reported$6.132.24
Operating cashflow per share$2.554.56
Capex per share$0.020.02
FCF per share$2.534.54
Free cash flow$m48.990.6
Net debt$m-282707
Book value equity$m1,017962
Book value per share$50.1248.18
Number of sharesm20.2919.96
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx30.84128.06
P/B LTMx3.595.97
P/S LTMx13.6422.61
P/FCF LTMx74.7663.36
EV/EBITDA LTMx20.4180.03
EV/Sales LTMx14.6725.39
Earnings Yield LTM%3.24%0.78%
FCF Yield%1.34%1.58%
Quality
ROE%12.23%5.22%
ROIC%2.42%1.35%
Operating margin%17.61%11.91%
Gross margin%97.54%107.11%
FCF/Sales%18.24%35.68%
Growth and momentum
EPS Growth YoY%-+8.21%
Sales Growth YoY%+60.40%+1.03%
Net Income Growth YoY%-+5.93%
FCF Growth%-36.82%+195.10%
Operating Profit Growth%-+72.59%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx0.110.08
Net Debt/EBITDAx1.4313.64
EBIT/Net interestx10.015.73
Net debt/market cap%-7.71%12.32%
Net debt/Equityx-0.280.73
Gross debt/equityx0.441.20

ETFs that hold Ligand Pharmaceuticals

FundTickerPosition#Weight
Invesco S&P SmallCap Momentum ETFXSMO42.26%
Congress SMID Growth ETFCSMD102.83%
Nomura Small and Mid Cap ETFSMDC12.07%
FundX Future Fund Opportunities ETFFFOX32.09%
Invesco S&P SmallCap Health Care ETFPSCH53.37%
Russell Investments Exchange Traded Funds - Russell Investments US Small Cap Equity ETFRUSC10.68%
Acuitas Small Cap Active ETFAIMS21.76%

Funds with Ligand Pharmaceuticals among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price286.85 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Websiteligand.com
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Ligand Pharmaceuticals Incorporated (LGND)

LGND · NASDAQ · Healthcare
286.85 USD-0.03%
Sign up to track this stock
Benchmarks
KvantraRank65
Market cap5.74B
P/E NTMN/A
P/E TTM128.1
KvantraRank?65 / 100
Value
60
Quality
61
Momentum
78
Financialsin USD
20242025TTM2026E
ETFs that hold Ligand Pharmaceuticals
FundTickerPosition#Weight
Invesco S&P SmallCap Momentum ETFXSMO42.26%
Congress SMID Growth ETFCSMD102.83%
Nomura Small and Mid Cap ETFSMDC12.07%
FundX Future Fund Opportunities ETFFFOX32.09%
Invesco S&P SmallCap Health Care ETFPSCH53.37%
Russell Investments Exchange Traded Funds - Russell Investments US Small Cap Equity ETFRUSC10.68%
Acuitas Small Cap Active ETFAIMS21.76%

Funds with Ligand Pharmaceuticals among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current286.85 USD
Upside
Price consensus
Last year average price target
Current price286.85 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Websiteligand.com
IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free